DK2056874T3 - Tumorterapi med et anti-vegf-antistof - Google Patents

Tumorterapi med et anti-vegf-antistof

Info

Publication number
DK2056874T3
DK2056874T3 DK07786693.7T DK07786693T DK2056874T3 DK 2056874 T3 DK2056874 T3 DK 2056874T3 DK 07786693 T DK07786693 T DK 07786693T DK 2056874 T3 DK2056874 T3 DK 2056874T3
Authority
DK
Denmark
Prior art keywords
vegf antibody
tumor therapy
tumor
therapy
vegf
Prior art date
Application number
DK07786693.7T
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2056874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2056874T3 publication Critical patent/DK2056874T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK07786693.7T 2006-08-21 2007-08-17 Tumorterapi med et anti-vegf-antistof DK2056874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (1)

Publication Number Publication Date
DK2056874T3 true DK2056874T3 (da) 2012-10-15

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07786693.7T DK2056874T3 (da) 2006-08-21 2007-08-17 Tumorterapi med et anti-vegf-antistof

Country Status (29)

Country Link
US (6) US20080050385A1 (da)
EP (2) EP2441472B1 (da)
JP (3) JP2010501498A (da)
KR (1) KR101136763B1 (da)
CN (1) CN101505792B (da)
AR (1) AR062419A1 (da)
AU (1) AU2007287794B2 (da)
BR (1) BRPI0715829A2 (da)
CA (1) CA2660681A1 (da)
CL (1) CL2007002404A1 (da)
CO (1) CO6150193A2 (da)
CR (1) CR10590A (da)
DK (1) DK2056874T3 (da)
ES (2) ES2392630T3 (da)
HK (1) HK1134441A1 (da)
IL (2) IL196810A0 (da)
MA (1) MA30654B1 (da)
MX (1) MX2009001715A (da)
MY (1) MY150756A (da)
NO (1) NO20090450L (da)
NZ (1) NZ574580A (da)
PE (1) PE20080911A1 (da)
PL (1) PL2056874T3 (da)
RU (1) RU2528884C2 (da)
SG (1) SG174090A1 (da)
SI (1) SI2056874T1 (da)
TW (2) TW201107346A (da)
WO (1) WO2008022746A1 (da)
ZA (1) ZA200901200B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1282443T1 (sl) * 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070085855A (ko) * 2004-12-07 2007-08-27 제넨테크, 인크. Ｈｅｒ 억제제를 이용한 치료를 위한 환자 선택 방법
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
BRPI0606542A8 (pt) 2005-02-23 2018-03-20 Genentech Inc métodos para aumentar o tempo de progressão de uma doença (ttp)
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
PL2056874T3 (pl) * 2006-08-21 2013-02-28 Hoffmann La Roche Leczenie nowotworu przeciwciałem przeciw VEGF
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
CA2804348A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
DK2606070T3 (da) * 2010-08-20 2017-03-27 Novartis Ag Antistoffer for den epidermiske vækstfaktorreceptor 3 (HER3)
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
KR102099991B1 (ko) 2011-10-14 2020-04-14 제넨테크, 인크. Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
RU2014125520A (ru) * 2011-12-05 2016-02-10 Ф. Хоффманн-Ля Рош Аг Биомаркеры плазмы крови в случае комбинированной терапии бевацизумабом для лечения рака груди
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) * 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
TW202138007A (zh) 2017-01-17 2021-10-16 美商建南德克公司 皮下her2抗體調配物
EP3589661B1 (en) 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
JP2023541141A (ja) * 2020-09-04 2023-09-28 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ がんを治療するための組み合わせ組成物及び方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
EP0907649A1 (en) 1996-06-27 1999-04-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
WO1998017797A1 (en) 1996-10-18 1998-04-30 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2256935T3 (es) 1997-04-07 2006-07-16 Genentech, Inc. Anticuerpos humanizadores y procedimiento para producirlos.
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
SK17282000A3 (sk) 1998-05-15 2002-04-04 Imclone Systems Incorporated Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
PT1135498E (pt) 1998-11-18 2008-04-30 Genentech Inc Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
ES2243228T3 (es) 1999-02-11 2005-12-01 Pfizer Products Inc. Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
JP5623681B2 (ja) 1999-05-14 2014-11-12 ジェネンテック， インコーポレイテッド 抗−ＥｒｂＢ２抗体による治療
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK1189634T3 (da) 1999-06-25 2007-06-25 Genentech Inc Behandling af prostatacancer med anti-ErbB2-antistoffer
CN101518653B (zh) 1999-06-25 2015-08-19 基因技术股份有限公司 使用抗ErbB抗体-类美坦素偶联物的治疗方法
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20060036086A1 (en) 2002-03-12 2006-02-16 Jain Rakesh K Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
EP1501856B1 (en) 2002-04-10 2012-12-19 Genentech, Inc. Anti-her2 antibody variants
CN1829741A (zh) 2003-05-30 2006-09-06 健泰科生物技术公司 利用抗－vegf抗体的治疗
WO2005000090A2 (en) 2003-05-30 2005-01-06 Medi-Screw, Inc. Medical implant systems
CA2534055A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
BRPI0515670A (pt) * 2004-10-04 2008-07-29 Genentech Inc anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
NZ564243A (en) * 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PL2056874T3 (pl) * 2006-08-21 2013-02-28 Hoffmann La Roche Leczenie nowotworu przeciwciałem przeciw VEGF
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
EP2056874B1 (en) 2012-09-19
MX2009001715A (es) 2009-02-25
AU2007287794A1 (en) 2008-02-28
CL2007002404A1 (es) 2008-04-18
CR10590A (es) 2009-03-20
RU2009110102A (ru) 2010-09-27
US20080050385A1 (en) 2008-02-28
TW200825106A (en) 2008-06-16
IL196810A0 (en) 2011-08-01
AU2007287794B2 (en) 2013-03-28
ES2546066T3 (es) 2015-09-18
US20150239969A1 (en) 2015-08-27
ZA200901200B (en) 2013-08-28
ES2392630T3 (es) 2012-12-12
EP2441472A1 (en) 2012-04-18
US20100285010A1 (en) 2010-11-11
PE20080911A1 (es) 2008-08-15
CN101505792B (zh) 2012-10-03
EP2056874A1 (en) 2009-05-13
SG174090A1 (en) 2011-09-29
CO6150193A2 (es) 2010-04-20
JP2013163687A (ja) 2013-08-22
KR20090032136A (ko) 2009-03-31
CN101505792A (zh) 2009-08-12
HK1134441A1 (en) 2010-04-30
NZ574580A (en) 2011-12-22
BRPI0715829A2 (pt) 2013-07-23
EP2441472B1 (en) 2015-06-10
MY150756A (en) 2014-02-28
CA2660681A1 (en) 2008-02-28
AR062419A1 (es) 2008-11-05
RU2528884C2 (ru) 2014-09-20
PL2056874T3 (pl) 2013-02-28
US20110223159A1 (en) 2011-09-15
SI2056874T1 (sl) 2012-12-31
TW201107346A (en) 2011-03-01
MA30654B1 (fr) 2009-08-03
WO2008022746A1 (en) 2008-02-28
IL238045A0 (en) 2015-05-31
JP2015214582A (ja) 2015-12-03
JP2010501498A (ja) 2010-01-21
KR101136763B1 (ko) 2012-04-24
NO20090450L (no) 2009-02-27
US20180251536A1 (en) 2018-09-06
US20130183292A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
DK2056874T3 (da) Tumorterapi med et anti-vegf-antistof
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
LTC2152290I2 (lt) Anti-il-5 antikūnų skyrimo būdai
CY2018004I2 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK2131860T3 (da) Anti-sclerostin-antistoffer
IL205547A0 (en) Anti-vegf antibody compounds and methods
DK2196541T3 (da) Anti-glypican-3-antistof med forbedret kinetik i plasmaet
NO344963B1 (no) Humanisert antistoff
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK2139987T5 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2035369T3 (da) Terapeutiske
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0715703A2 (pt) anticorpos anti-c5ar com propriedades melhoradas
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
ATE522514T1 (de) Dihydropyran-2-onverbindungen mit antitumorwirkung
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0807858A2 (pt) Anticorpo de modificação de doença cancerosa
GB0815788D0 (en) Therapeutic antibodies
DE502007001073D1 (de) Gurtaufroller mit kupplungsblockade